Discover
more about NexpowderTM*

Enhance your practice post-webinar

Thank you for joining us in the recent ESGENA Medtronic joint webinar dedicated to exploring the innovative Nexpowder™* technology. We are thrilled to see your interest in enhancing clinical practice and patient care with this cutting-edge endoscopic hemostatic solution.

This page is designed to provide you with all the information and resources you need to fully integrate Nexpowder™* into your practice. Dive in to learn more, access valuable educational materials and discover how Nexpowder™* can make a significant difference in managing gastrointestinal bleeding.

In case you missed the webinar, you can follow this link to watch the recording. 

Nexpowder™* endoscopic hemostatic system overview1,2,5

The Nexpowder™* endoscopic hemostatic system is a noncontact, nonthermal and nontraumatic hemostatic powder sprayed through a catheter.1,2,5

Featuring a proprietary powder-coating technology, Nexpowder™* minimizes catheter clogging and particle scattering1,2, giving you more control and adequate visibility2,4,5.

Hemostatic powder technology that puts you in control.1-4

The Nexpowder™* endoscopic hemostasis system is a powder that can be sprayed to an ulcer site, applying an endoscopic hemostatic agent. As a hydrophilic biocompatible adhesive material, it is composed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran. 

The Nexpowder™* system forms the adhesive gel after making contact with the water or blood by reversible crosslinking. Crosslinked gel helps prevent bleeding, loss of body fluid and contamination of the ulcer site by adhering to the bleeding site in the gastrointestinal tract and then gel degrades within 1 day to 3 days.1,3

Nexpowder™* medical education

We're thrilled to introduce our comprehensive eLearning course designed specifically for nurses looking expand their expertise in endoscopic hemostasis with Nexpowder™*.

This innovative course offers an interactive module, insightful case studies and practical demonstrations to help you seamlessly integrate Nexpowder™* into your clinical practice. 

Begin your journey today and empower your practice with the latest in endoscopic solutions! 

In this online training, you will learn about:

  • Nexpowder™* product and technology 
  • Nexpowder™* clinical efficiency 
  • Indications for Nexpowder™*
  • Product handling
  • Best practice

How to use Nexpowder™*

These instructions provide a step-by-step guide on how to setup and use the Nexpowder™* endoscopic hemostatic system. 

Watch the instructional video or download the procedural guide.

Discover the transformative power of Nexpowder™* in real clinical settings through Nexpowder™* being used to manage acute gastrointestinal bleeding.

Watch now to see Nexpowder™*'s potential in enhancing your practice!

Watch the video
Nexpowder™* endoscopic hemostatic system

Indications:
Nexpowder™* is used for most GI bleeding. The device is applied during an endoscopic procedure and can cover ulcer or bleeding sites. The device is not intended for use in patients with variceal bleeding. Note: Do not use this device for any purpose other than stated intended use.

Contraindications:
Because the Nexpowder™* system includes lactose, it is contraindicated in patients who have galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption and they would be at risk of having nausea, bloating and diarrhea. Because the Nexpowder™* system includes Brilliant Blue FCF, it must not be used in patients with known hypersensitivity to brilliant blue FCF.

Potential complications:
Those associated with gastrointestinal endoscopy include, but are not limited to: hemorrhage, perforation, aspiration, fever, infection, allergic reaction and foreign body sensation in the digestive tract.

Warning:
Nexpowder™* has not been approved for use in pregnant women, nursing mothers and pediatric population and there is no safety or efficacy data in these groups.

Patients that are on antithrombotic medication may be at an increased risk of re-bleeding. Take individual patient needs and relevant clinical guidelines into account when managing antithrombotic agents for endoscopic procedures. Consider consulting the physician responsible for the antithrombotic if needed.

This medical device is designed for single use only. Attempts to resterilize and/or reuse may lead to device failure and/or transmission of disease.

Important: Always refer to the Instructions For Use (IFU) packaged with the product for complete instructions, indications, contraindications, warnings and precautions.

References

™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company

  1. Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May;51(5):458-462
  2. Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec;7(12):E1763-E1767
  3. Nexpowder Instructions for Use Approved 2024.02
  4. Bang B, Lee E, Maeng J, et al. - Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model.
  5. Ian M. Gralnek, Jean-Marc Dumonceau, Ernst J. Kuipers, Angel Lanas, David S. Sanders, Matthew Kurien, Gianluca Rotondano, Tomas Hucl, Mario Dinis-Ribeiro, Riccardo Marmo, Istvan Racz, Alberto Arezzo, Ralf-Thorsten Hoffmann, Gilles Lesur, Roberto de Franchis, Lars Aabakken, Andrew Veitch, Franco Radaelli, Paulo Salgueiro, Ricardo Cardoso, Luís Maia, Angelo Zullo, Livio Cipolletta, Cesare Hassan - Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).  Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com.  Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.